Mantle cell lymphoma is an aggressive and incurable subtype of non-Hodgkin B cell lymphoma.
protein levels, RNA interference (RNAi) therapy may offer a viable means to kill cancer at the mRNA level. When used in combination with current treatments, RNAi may help to induce remission using lower doses of chemotherapy, which would better preserve treatment options upon relapse. Furthermore, an RNAi approach is apropos because mantle cell lymphoma cells overexpress several genes that encourage cell proliferation. 13, 14 For example, Cyclin D1 (CCND1), a protein that facilitates cell cycle progression, is overexpressed in more than 90% of mantle cell lymphoma patients due to a t(11;14) (q13;q32) translocation of Cyclin D1 and immunoglobulin heavy chain genes (IgH). 5 Additionally, the anti-apoptotic proteins Bcl-2 and Mcl-1 are commonly overexpressed in mantle cell lymphoma and may contribute to chemotherapy resistance. [15] [16] [17] Although protein inhibitors of Bcl-2 and Mcl-1 have shown promise, [18] [19] [20] [21] [22] downregulation at the mRNA level with a viable delivery system has been overlooked.
Unfortunately, B-cells are notoriously difficult to transfect, and only a limited number of studies have reported on short interfering RNA (siRNA) delivery to lymphoma cells. [23] [24] [25] [26] [27] For example, we have previously described the ability of siRNA-loaded lipid nanoparticles (LNPs) to silence Mcl-1 expression and increase the apoptosis rates of mantle cell lymphoma. 28 Because our LNPs are potent transfection agents, [29] [30] [31] [32] [33] we herein investigate their use for multiplexed gene silencing in mantle cell lymphoma cells. Our data show that the simultaneous silencing of three key genes involved in mantle cell lymphoma growth induces apoptosis in the majority of lymphoma cells. As such, siRNA "cocktails" may hold promise as a mechanistically distinct addition to current mantle cell lymphoma treatment regimens.
| R E SU LTS
In this study, we sought to identify an RNAi treatment with potential to enhance multi-pronged mantle cell lymphoma therapy. Mantle cell lymphoma patients have a poor prognosis and patients that do not participate in clinical trials have a life expectancy of only 3 years after initial diagnosis. 2, 4 The genetic mutations present in many mantle cell lymphoma patients make this malignancy an ideal candidate for RNA interference therapy. 25, 34 Although lymphocytes can be particularly challenging to transfect compared to monocytes and adherent cells, we have previously established that lipidoid-containing LNPs facilitate gene silencing in mantle cell lymphoma cells. 28 In the present study, we first evaluated the ability of three lipidoids-303O 13 , 304O 13 , and 306O 13 ( Figure 1a) Figure 1 ). 306O 13 LNPs also silenced GAPDH (albeit more modestly) in MAVER-1 cells, a more aggressive human mantle cell lymphoma line, in a dose-responsive manner (Supporting Information Figure 2 ). We anticipate that this ability to mediate silencing in lymphoma cells with varying degrees of gene mutation will be important in developing a broadly applicable therapeutic. Because of their higher potency compared to 303O 13 and 304O 13 LNPs, we opted to work with 306O 13 LNPs for the remainder of our studies. A time point study was conducted to examine the dura- After establishing that three-tailed 306O 13 is the most potent LNP for gene silencing in mantle cell lymphoma cells, we turned our focus to three genes that are upregulated in mantle cell lymphoma patients.
These included the cell cycle regulator, Cyclin D1, and the antiapoptotic proteins, B-cell lymphoma 2 (Bcl-2), and myeloid cell leukemia 1 (Mcl-1).
Cyclin D1 facilitates cell cycle progression from the G1 to the S phase through complex formation with Cyclin D kinases 4 and 6, which phosphorylate retinoblastoma 1. 35 Cyclin D1 overexpression occurs in more than 90% of mantle cell lymphoma patients as a consequence of a t (11;14) (q13;q32) translocation of Cyclin D1 and the IgH heavy chain. 36 This overexpression deregulates the cell cycle, leading to rapid progression from the G1 to the S phase and subsequent proliferation. It has been shown that Cyclin D1 downregulation leads to cell cycle arrest, apoptosis, and an increased sensitivity to chemotherapy. Cyclin D1 is one of three Cyclin D homologues, all of which regulate the G1 to S phase transition in the cell cycle. 44 It has been shown previously that knockdown of Cyclin D1 can cause a compensatory increase in Cyclin D2 expression. 23 Therefore, we sought to determine if the LNP-mediated silencing of Cyclin D1 in JeKo-1 cells provoked similar increases in the expression of homologues Cyclin D2 and Cyclin D3. Figure 3 shows Cyclin D expression following the delivery of siRNA specific against Cyclin D1 at a dose of 50 nM. We observed a decrease in Cyclin D1 (CCND1) levels, a 20-fold increase in Cyclin D2
(CCND2) levels, and no change in Cyclin D3 (CCND3) levels. This effect was dose-responsive, with an anti-Cyclin D1 siRNA dose of 100 nM inducing a 45-fold increase in Cyclin D2 expression (Supporting Information Figure 3 ).
This compensatory effect was mitigated by silencing Cyclin D2 in addition to Cyclin D1 ( Figure 3 ). By silencing both of these genes, expression of Cyclin D1 remained low, expression of Cyclin D3 was unchanged, and Cyclin D2 levels were brought back down, close to baseline levels. To control for any delivery vehicle effects in this however, that silencing Cyclin D2 would be necessary for effective therapy. This is because Cyclin D2 mRNA expression was more than 8,000-fold lower than Cyclin D1 levels in untreated samples (data not shown).
To determine whether Cyclin D2 siRNA was a necessary inclusion in a therapeutic siRNA cocktail, we measured JeKo-1 apoptosis rates following Cyclin D1 and Cyclin D2 protein silencing. We first measured the duration of Cyclin D1 mRNA silencing following a single 50 nM dose of siCCND1 to determine appropriate timing for the apoptosis measurement ( Figure 4a ). Cyclin D1 mRNA levels were silenced by 75% for 3 days before returning to baseline by day 6. We, therefore, chose a 4-day time point for the measurement of gene expression and apoptosis ( Figure 4b -d), which should provide enough time for silencing to affect apoptosis. Every sample except the untreated groups received a total siRNA dose of 200 nM to control for any delivery vehicle effects. That is, one group received 100 nM siCCND1 1 100 nM siControl, a second received 100 nM siCCND2 1 100 nM siControl, and a third received 100 nM siCCND1 1 100 nM siCCND2. Together, these data suggest that adding siCCND2 to the siRNA treatment regimen did not improve outcomes. Four days post-transfection, the "double" Cyclin D siRNA treatment did not result in more apoptosis than when silencing Cyclin D1 alone. In fact, as shown in Figure 4d , apoptosis rates were significantly higher in the siCCND1 group (55%) than in the siCCND1 1 siCCND2 group (25%). Similar results were observed when treating with total siRNA doses of 100 nM (data not shown). Therefore, we decided to target only Cyclin D1 instead of a Cyclin D1-D2 combination in future experiments.
| Multiplexed gene silencing improved apoptosis rates
In previous work, we showed that silencing Mcl-1 in JeKo-1 and MAVER-1 cells using siRNA-loaded LNPs caused cells to undergo apoptosis. 28 We thought it may be possible to improve upon these results by targeting multiple genes in one treatment, given the potency of our
LNPs. Therefore, we attempted to simultaneously knockdown Mcl-1, Cyclin D1, and another antiapoptotic protein, Bcl-2 using a cocktail of the three siRNAs. 
| Multiplexed gene silencing reduced cell proliferation

| D I SCUSSION
Mantle cell lymphoma is one of the most deadly subtypes of B-cell non-Hodgkin lymphoma. 1 Although new treatments (e.g., rituximab) have improved outcomes over the last 20 years, survival in the general patient population remains very low. 2, 4 As clinical therapies have progressed from chemotherapy to small molecules drugs to immunotherapy, RNA interference therapy remains an untapped clinical option with the potential to improve treatment outcomes through a unique therapeutic mechanism.
In this study, we formulated LNPs containing synthetic, ionizable, lipid-like materials, termed "lipidoids," to deliver siRNA to mantle cell lymphoma cells. Because lipidoid-containing LNPs had previously been shown to effectively silence genes in a variety of cell types, we sought to examine their ability to transfect notoriously difficult B-cells.
Although several groups have used nanotherapeutics to knockdown Cyclin D1 with siRNA or shRNA in mantle cell lymphoma, [23] [24] [25] 47 other genes have been largely overlooked.
We found that lipid nanoparticles formulated from the lipidoid 306O 13 mediate potent and durable silencing in human mantle cell lymphoma cells (Figure 1 ). We then used these lipidoid nanoparticles to examine the effect of silencing a trio of genes-Cyclin D1, Bcl-2, and
Mcl-1-on mantle cell lymphoma apoptosis and proliferation rates. The overexpression of Cyclin D1, which occurs in more than 90% of mantle cell lymphoma patients, 5, 36 is correlated with higher rates of tumor cell growth and decreased survival. 48 We also examined two anti-apoptotic had on Cyclin D1 expression (Figures 3 and 4) . Klier and colleagues found that Cyclin D1 exists at greater than 1,000-fold higher levels than Cyclin D2 in JeKo-1 cells. 53 Our qPCR analysis also determined that total Cyclin D1 mRNA existed at a much higher level compared to Cyclin D2 mRNA, regardless of treatment (data not shown). This likely explains why the upregulation of Cyclin D2 following the knockdown of Cyclin D1 does not preclude therapeutic effect (i.e., increased apoptosis). Because we found that silencing Cyclin D2 did not increase apoptosis rates (Figure 4d ), we chose not to include it as a target in siRNA cocktails.
Multiplexed gene silencing has not previously been attempted for the treatment of mantle cell lymphoma. Simultaneous silencing of multiple gene targets requires a delivery system that is sufficiently potent to induce therapeutic levels of protein knockdown without causing toxicity. Lipid delivery systems, particularly those with a permanent positive charge, can be associated with local toxicity, such as cell irritation and cell lysis, and systemic toxicity causing inflammatory cytokines to be released. 54 In this study, we demonstrate that a triple siRNA cocktail delivered with nanoparticles made from the ionizable lipidoid 306O 13 caused increased apoptosis and decreased proliferation in mantle cell lymphoma cells. Based on apoptosis rates ( Figure 5 ), it appears that silencing at least one protein from each pathway (i.e., Cyclin D1 plus either
Mcl-1 or Bcl-2) results in higher apoptosis rates than when Cyclin D1 is excluded. Figure 6 , however, shows greater reductions in proliferation 
| Lipidoid synthesis
Lipidoids were synthesized as described previously. 28 Briefly, three 
| Lipid nanoparticle formulation
Lipid nanoparticles were formulated as previously described. 28 Briefly, a lipid solution containing lipidoid, DSPC, cholesterol, and C14 PEG2000 (50:10:38.5:1.5 molar ratio) in ethanol with 5% sodium citrate buffer (pH 3-4) was added to an equal volume of siRNA diluted in sodium citrate buffer. The mixture was briefly vortexed and further diluted 1:1 in PBS (pH 7.4). 306O 13 LNPs were dialyzed for 4 hr in PBS. siRNA entrapment and particle size were determined using a Quant-iT Ribogreen RNA Reagent assay (Thermofisher Scientific) and dynamic light scattering, respectively. Particle sizes are reported as number mean.
| Cell culture
Immortalized human mantle cell lymphoma cell lines JeKo-1 and MAVER-1 were cultured at 378C in 5% CO 2 in RPMI 1640 with 20%
and 10% FBS, respectively. About 100 U/ml Penicillin Streptomycin was added to the cell culture media.
| Gene silencing experiments
Cells were seeded at 250,000 cells/ml in 12 or 24 well plates. LNPs were added such that they made up 10% of the final volume. At 
| Cell viability experiment
JeKo-1 cells were seeded at 250,000 cells/ml in 96 well plates and treated with LNPs as described above. After 24 hr, cell viability was quantified using a MTT Cell Proliferation Assay Kit (ATCC) and Synergy H1 Hybrid Reader (BioTek Instruments, Winooski, Vermont) following the manufacturer's protocol.
| Apoptosis experiment
Cells were seeded at 250,000 cells/ml. At several time points between 1 and 8 days following transfection with siRNA-loaded LNPs, the fraction of cells undergoing apoptosis was determined using an Alexa Fluor 488 Annexin V/Dead Cell Apoptosis Kit and BD Accuri C6 flow cytometer (BD Biosciences, San Jose, CA) following the manufacturer's protocol. FlowJo software was used for flow cytometry data analysis.
| Cell counting experiment
JeKo-1 cells were seeded at 250,000 cells/ml in 24 well plates. Cells were treated with 200 nM doses of total siRNA. The cell count per 20 ll aliquot was determined using a BD Accuri C6 flow cytometer with a HyperCyt Autosampler (Intellicyt, Albuquerque, NM) for high throughput processing. FlowJo software was used for flow cytometry data analysis.
| Statistical analysis
All statistical analysis was performed using GraphPad Prism (La Jolla, CA) software. Error bars represent standard deviation (n 5 3). 
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